Eric J. Kunkel, et al . ASSAY and Drug Development Technologies Vol 2, Num 4, 2004
description
Transcript of Eric J. Kunkel, et al . ASSAY and Drug Development Technologies Vol 2, Num 4, 2004
![Page 1: Eric J. Kunkel, et al . ASSAY and Drug Development Technologies Vol 2, Num 4, 2004](https://reader035.fdocuments.in/reader035/viewer/2022081811/56813c0d550346895da57c93/html5/thumbnails/1.jpg)
Rapid Structure-Activity and Selectivity Analysis Rapid Structure-Activity and Selectivity Analysis of Kinase Inhibitors by BioMAP Analysis in of Kinase Inhibitors by BioMAP Analysis in Complex Human Primary Cell-Based ModelsComplex Human Primary Cell-Based Models
Eric J. Kunkel, Eric J. Kunkel, et alet al. . ASSAY and Drug ASSAY and Drug Development Technologies Vol 2, Num 4, Development Technologies Vol 2, Num 4, 20042004
Presented by Ankit GargPresented by Ankit Garg
![Page 2: Eric J. Kunkel, et al . ASSAY and Drug Development Technologies Vol 2, Num 4, 2004](https://reader035.fdocuments.in/reader035/viewer/2022081811/56813c0d550346895da57c93/html5/thumbnails/2.jpg)
The ProblemThe Problem
Protein kinases are attractive drug Protein kinases are attractive drug targets because of their central role in targets because of their central role in controlling signaling pathways in all cells.controlling signaling pathways in all cells.
Kinase inhibitors tend to interact with the Kinase inhibitors tend to interact with the ATP-binding pocket and thus tend to ATP-binding pocket and thus tend to inhibit multiple targets.inhibit multiple targets.
![Page 3: Eric J. Kunkel, et al . ASSAY and Drug Development Technologies Vol 2, Num 4, 2004](https://reader035.fdocuments.in/reader035/viewer/2022081811/56813c0d550346895da57c93/html5/thumbnails/3.jpg)
BioMAP ProcessBioMAP Process